GANX (Gain Therapeutics) Long-Term Debt: $0.27 Mil (As of Mar. 2026)


GANX Gain Therapeutics Inc GANX
32 GF Score
Price $1.80
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics Long-Term Debt?

Gain Therapeutics GANX -0.87% 32 Long-Term Debt is $0.27 Mil as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Gain Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.27 Mil.

Gain Therapeutics's quarterly Long-Term Debt increased from Sep. 2025 ($0.30 Mil) to Dec. 2025 ($0.30 Mil) but then declined from Dec. 2025 ($0.30 Mil) to Mar. 2026 ($0.27 Mil).

Gain Therapeutics's annual Long-Term Debt declined from Dec. 2023 ($0.45 Mil) to Dec. 2024 ($0.33 Mil) and declined from Dec. 2024 ($0.33 Mil) to Dec. 2025 ($0.30 Mil).

Gain Therapeutics  (NAS:GANX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Gain Therapeutics Long-Term Debt Related Terms

Gain Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics Long-Term Debt Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.59 0.50 0.45 0.33 0.30

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.33 0.30 0.30 0.27
GANX
32GF Score
Gain Therapeutics Inc GANX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.27 Mil mean?
Gain Therapeutics (GANX) has a Long-Term Debt of $0.27 Mil as of Mar. 2026.
Is Gain Therapeutics' Long-Term Debt too high?
Gain Therapeutics' current Long-Term Debt is $0.27 Mil. Overall, Gain Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' Long-Term Debt compare to HYFT and ELTX?
Gain Therapeutics' Long-Term Debt of $0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Gain Therapeutics's current Long-Term Debt is $0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current Long-Term Debt of $0.27 Mil. The current Long-Term Debt is $0.27 Mil. Gain Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current Long-Term Debt is $0.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
32GF Score

Get the complete analysis for GANX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price